Search results
Jan 4, 2024 · 2023 was a strong year for innovative new drugs, with new medications for Alzheimer’s disease, weight loss, and the first treatment based on the gene-editing technology CRISPR.
- kathy.katella-cofrancesco@yale.edu
- Paxlovid. Paxlovid is Pfizer’s brand name for an antiviral oral medication (in pill form) that combines two generic drugs, nirmatrelvir and ritonavir.
- Remdesivir. The antiviral treatment remdesivir, sold under the brand name Veklury, was the first COVID-19 therapy to get full FDA approval, and, so far, it's still the only one.
- Molnupiravir. Molnupiravir, also known by the brand name Lagevrio, was developed by Merck and Ridgeback Biotherapeutics. It was heralded as a potential game-changer when the companies announced their initial clinical trial results in 2021.
- Evusheld (not currently authorized) Evusheld is a monoclonal antibody that was granted FDA authorization in December 2021; however, it was halted in January 2023 until further notice.
- What Is Wegovy and How Does It Work?
- Who Can Take Wegovy?
- What Are The Risks and Benefits of Wegovy?
- How Long Can You Take Wegovy?
- Anti-Obesity Medication Management: An Evolving Landscape
- Paying For Anti-Obesity Medications
- GeneratedCaptionsTabForHeroSec
Wegovy is the brand name for the high-dose injectable peptide hormone molecule known as semaglutide, a medication that was previously approved by the FDA under the brand names Rybelsus (oral) and Ozempic (lower-dose injection) for the treatment of type 2 diabetes. Injectable semaglutide eliminates the strict guidelines for ingesting on an empty sto...
Wegovy, like all other prescription medications designated for the treatment of obesity, is approved for use in those with a body mass index (BMI) of 30 kg/m2 or greater, or those with a BMI of 27 kg/m2with a weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Phase 3 clinical trials of Wegovy, dubbed the STEP (Semaglutide Treatment Effect in People with Obesity) trials, were conducted in a variety of clinical scenarios, each varying slightly in the study population and study design. The widely reported STEP 1 trial, the results of which were published in the New England Journal of Medicine, demonstrated...
Wegovy is one of six medications currently approved by the FDA for the long-term treatment of obesity. As such, it can be used for as long as it remains beneficial for weight loss and/or weight maintenance and is not causing intolerable side effects. The first GLP-1 RA medication to gain FDA approval was exenatide in 2005; since then, multiple GLP-...
Wegovy is the latest in a line of medications, starting with phentermine in 1959, that have achieved FDA approval for the treatment of obesity. Currently there are 10 FDA-approved anti-obesity medications in the US: phentermine, diethylpropion, benzphetamine, phendimetrazine, orlistat, phentermine/topiramate ER (Qsymia), bupropion/naltrexone (Contr...
For those who do prescribe anti-obesity pharmacotherapy, challenges arise with the exorbitant cost of some of the newer therapeutics, as well as refusal of many private and public insurers to cover anti-obesity medications. Sometimes patients or their advocates may have success in lobbying their employers to opt into insurance coverage for obesity ...
Wegovy is a high-dose injectable peptide hormone that reduces appetite and promotes weight loss. Learn about its benefits, risks, side effects, and how it compares to other anti-obesity medications.
- hhp_info@health.harvard.edu
Dec 14, 2023 · The first CRISPR gene-editing therapy, a new Alzheimer’s drug and RSV vaccines were among the big developments in medicine this year.
Mar 18, 2024 · SINGAPORE – There are new treatments that can significantly slow down the progression of kidney disease, giving hope to the hundreds of thousands of people in Singapore suffering from...
Oct 19, 2021 · MIT researchers show that injured cancer cells treated with low-dose chemotherapy drugs can activate T cells to destroy tumors in mice. This approach could improve immunotherapy for more types of cancer and prevent tumor recurrence.
Dec 8, 2023 · The FDA on Friday also approved a second treatment for sickle cell disease, called Lyfgenia, a gene therapy from drugmaker Bluebird Bio. Both treatments work by genetically modifying a...
